Anthony Hollenberg Takes on New Roles at New York-Presbyterian/Weill Cornell Medical Center

Hollenberg_Headshot

Anthony Hollenberg, MD, has been appointed chairman of the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and physician-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center.

Recruited as the Weill Chairman, Hollenberg will lead the institutions’ largest clinical and academic department, overseeing 16 divisions and nearly 2,600 physicians and scientists who exemplify excellence in their medical disciplines. He will leverage opportunities afforded by Weill Cornell Medicine and NewYork-Presbyterian’s clinical expansion to enhance the department’s distinguished clinical and research programs. And he will also seek to recruit outstanding physicians and scientists to complement the team already assembled in the Weill Department of Medicine, and nurture the next generation of medical leaders through its medical education programs—including residency programs and fellowships in medical subspecialties.

Currently, Hollenberg is at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, where he is chief of the Division of Endocrinology, Diabetes and Metabolism, and vice chair for mentoring in its Department of Medicine. He is also currently director of Clinical and Translational Training Programs at Harvard Catalyst, the Clinical and Translational Science Center at Harvard Medical School, where he is a professor of medicine.

Hollenberg is also an associate editor for the Endocrine Society journal, Endocrinology.

As an endocrinologist interested in thyroid disorders, Hollenberg investigates the physiological and molecular underpinnings of metabolism, with a particular focus on understanding how thyroid hormones regulate metabolism and lipid levels, and affect body weight. Additionally, his lab is developing protocols to develop functioning thyroid tissue from embryonic stem cells. An accomplished basic and translational researcher, Hollenberg uses findings gleaned from his basic science research to help his patients, who then further inform his work in the lab.

“It’s an enormous honor to be selected for this position,” Hollenberg says. “Weill Cornell Medicine and NewYork-Presbyterian have nurtured an incredible culture for excellence in science and medicine, which is reflected in the exemplary nature of their entire biomedical enterprise and the resources the institutions provide for innovation. I consider it a privilege to take on these roles, and I’m thrilled about this opportunity.”

Hollenberg plans on leveraging the institutions’ increasing reach to foster new opportunities for scientific discovery and strengthen existing collaborations between investigators at Weill Cornell Medicine and NewYork-Presbyterian and their colleagues at Memorial Sloan Kettering, The Rockefeller University and Hospital for Special Surgery, as well as Cornell University in Ithaca and Cornell Tech on Roosevelt Island. The Weill Department of Medicine is already a hub for cutting-edge biomedical research, with total research grants exceeding $44 million in 2016.

Board certified in internal medicine, Hollenberg has published more than 80 original studies in journals and has also contributed 25 book chapters and reviews. He begins his new positions Feb. 1, 2018.

 

You may also like

  • Holly A. Ingraham, PhD, Receives FASEB Excellence in Science Lifetime Achievement Award

    Endocrine Society member Holly A. Ingraham, PhD, is the recipient of the FASEB Excellence in Science Lifetime Achievement Award. On April 8, the organization announced the winners of its 2024 Excellence in Science Awards, which highlight outstanding achievements by women in biological sciences who demonstrate not only excellence and innovation in their research fields, but…

  • Endocrine Society Celebrates Special Diabetes Program Extension

    The Endocrine Society applauds Congress for approving the first funding increase for the Special Diabetes Program in two decades. The U.S. Senate voted Friday March 8 to extend the program, which supports both diabetes care and research into type 1 diabetes, until the end of 2024. This is part of the six-bill package funding several…

Find more in